Phase II Study of Mifepristone (RU486) in Refractory Ovarian Cancer
Authors:
- Thomas F. RoceretoTRThomas F. Rocereto
- Howard M. SaulHSHoward M. Saul
- James A. AikinsJAJames A. Aikins
- James PaulsonJPJames Paulson
- 1 June 2000
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 77 (3) , 429-432
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or PaclitaxelJournal of Clinical Oncology, 1999
- Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.Journal of Clinical Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Treatment of unresectable meningiomas with the antiprogesterone agent mifepristoneJournal of Neurosurgery, 1991
- Endocrine Factors in Common Epithelial Ovarian Cancer*Endocrine Reviews, 1991
- CA-125 Values Predictive of Clinical Response during Second-Line Chemotherapy for Epithelial Ovarian CancerAmerican Journal of Clinical Oncology, 1989
- The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.Journal of Clinical Oncology, 1988
- Ovarian cancerCurrent Problems in Cancer, 1987